Back to top
more

Chemed (CHE)

(Real Time Quote from BATS)

$542.54 USD

542.54
9,790

-2.29 (-0.42%)

Updated Jun 11, 2024 10:43 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (36 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Encompass Health (EHC) to Spin Off Unit to Streamline Business

by Zacks Equity Research

Encompass Health (EHC) is exploring strategic alternatives to split its home health and hospice business from the original corporate structure to streamline operations.

DVA vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

DVA or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Looking for a Growth Stock? 3 Reasons Why Chemed (CHE) is a Solid Choice

by Zacks Equity Research

Chemed (CHE) possesses solid growth attributes, which could help it handily outperform the market.

Chemed (CHE) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Encompass Health (EHC) to Build Rehabilitation Hub in Illinois

by Zacks Equity Research

Encompass Health (EHC) to construct an inpatient rehabilitation hospital with a capacity of 40 in Shiloh Illinois, which will be run as a joint venture with BJC HealthCare.

DVA vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Is Chemed (CHE) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Chemed (CHE) could produce exceptional returns because of its solid growth attributes.

Chemed's (CHE) Shares Up on Q3 Earnings and Revenue Beat

by Zacks Equity Research

Chemed (CHE) reports solid revenue growth across key subsidiaries in third-quarter results.

Chemed (CHE) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 21.80% and 2.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More

by Zacks Equity Research

Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-19-related services are likely to have gained from the same.

Chemed (CHE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DVA vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

DVA vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

DVA vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Why Is Chemed (CHE) Up 2.9% Since Last Earnings Report?

by Zacks Equity Research

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DVA vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Chemed's (CHE) VITAS Business Strong Amid Coronavirus Crisis

by Zacks Equity Research

Amid the pandemic scenario, Chemed's (CHE) VITAS and Roto-Rooter both have been classified as essential services.

DVA vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Q2 Earnings Beat Estimates, Margins Decline

by Zacks Equity Research

Chemed (CHE) witnesses solid revenue growth across key subsidiaries in Q2 earnings.

Chemed (CHE) Beats Q2 Earnings Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 16.36% and -1.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Chemed (CHE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DVA or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Chemed (CHE) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Chemed (CHE) closed at $467.36, marking a +1.62% move from the previous day.

Chemed (CHE) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Chemed (CHE) closed the most recent trading day at $450, moving +1.12% from the previous trading session.